Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2013 Aug;24(8):2131-6.
doi: 10.1093/annonc/mdt163. Epub 2013 May 9.

Long-term Follow-Up of a Phase III Study Comparing Radiotherapy With or Without Weekly Oxaliplatin for Locoregionally Advanced Nasopharyngeal Carcinoma

Affiliations
Free article
Clinical Trial

Long-term Follow-Up of a Phase III Study Comparing Radiotherapy With or Without Weekly Oxaliplatin for Locoregionally Advanced Nasopharyngeal Carcinoma

X Wu et al. Ann Oncol. .
Free article

Abstract

Background: Previous results from our trial showed that adding oxaliplatin to radiotherapy (RT) increased survival in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) at 2 years. Here, we present the data of long-term efficacy and late toxic effects.

Patients and methods: Between January 2001 and January 2003, 115 Patients with nonkeratinizing/undifferentiated locoregionally advanced NPC were randomly to receive either RT alone (n = 56) or plus concurrent oxaliplatin 70 mg/m(2) weekly for six cycles (n = 59).

Results: After a median follow-up of 114 months (range 18-139 months), the 5-year overall survival (OS) and metastasis-free survival (MFS) rates in the concurrent chemoradiotherapy (CCRT) group were significantly higher than those observed in the RT-alone group (OS, 73.2% versus 60.2%, P = 0.028; MFS, 74.7% versus 63.0%, P = 0.027). However, CCRT did not improve locoregional failure-free survival significantly. Subgroup analyses showed that the superiorities of CCRT mainly existed in the T3-4N0-1 stage subgroup (OS: HR = 0.394, P = 0.034). The grade 3/4 late toxic effects were similar in the two groups.

Conclusion(s): The long-term follow-up data confirms the role of CCRT as a treatment of locoregionally advanced NPC. Oxaliplatin can be considered as an alternative optional therapeutic regimen for these patients due to its high efficiency and low toxic effect.

Keywords: concurrent chemotherapy; nasopharyngeal carcinoma; oxaliplatin; radiotherapy.

Similar articles

See all similar articles

Cited by 39 articles

See all "Cited by" articles

Publication types

Feedback